Go to
JCI Insight
Citations to this article
Joaquin Mateo, … , Suzanne Carreira, Johann S. de Bono
Published December 24, 2019
Citation Information: J Clin Invest. 2020;130(4):1743-1751. https://doi.org/10.1172/JCI132031.
Citation Information: J Clin Invest. 2020;130(4):1743-1751. https://doi.org/10.1172/JCI132031.
Abstract
The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, also studying matching, same-patient, diagnostic, and mCRPC biopsies following treatment. We profiled 470 treatment-naive prostate cancer diagnostic biopsies and, for 61 cases, mCRPC biopsies, using targeted and low-pass whole-genome sequencing (n = 52). Descriptive statistics were used to summarize mutation and copy number profile. Prevalence was compared using Fisher’s exact test. Survival correlations were studied using log-rank test. TP53 (27%) and PTEN (12%) and DDR gene defects (BRCA2 7%; CDK12 5%; ATM 4%) were commonly detected. TP53, BRCA2, and CDK12 mutations were markedly more common than described in the TCGA cohort. Patients with RB1 loss in the primary tumor had a worse prognosis. Among 61 men with matched hormone-naive and mCRPC biopsies, differences were identified in AR, TP53, RB1, and PI3K/AKT mutational status between same-patient samples. In conclusion, the genomics of diagnostic prostatic biopsies acquired from men who develop mCRPC differ from those of the nonlethal primary prostatic cancers. RB1/TP53/AR aberrations are enriched in later stages, but the prevalence of DDR defects in diagnostic samples is similar to mCRPC.
Authors
Joaquin Mateo, George Seed, Claudia Bertan, Pasquale Rescigno, David Dolling, Ines Figueiredo, Susana Miranda, Daniel Nava Rodrigues, Bora Gurel, Matthew Clarke, Mark Atkin, Rob Chandler, Carlo Messina, Semini Sumanasuriya, Diletta Bianchini, Maialen Barrero, Antonella Petermolo, Zafeiris Zafeiriou, Mariane Fontes, Raquel Perez-Lopez, Nina Tunariu, Ben Fulton, Robert Jones, Ursula McGovern, Christy Ralph, Mohini Varughese, Omi Parikh, Suneil Jain, Tony Elliott, Shahneen Sandhu, Nuria Porta, Emma Hall, Wei Yuan, Suzanne Carreira, Johann S. de Bono
Total citations by year
Citation information
Citations to this article (145)
| Title and authors | Publication | Year |
|---|---|---|
|
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages
Pedrani M, Barizzi J, Salfi G, Nepote A, Testi I, Merler S, Castelo-Branco L, Mestre RP, Turco F, Tortola L, Theurillat JP, Gillessen S, Vogl U |
International Journal of Molecular Sciences | 2025 |
|
Autophagy Associated Genes (ARGs) ‐Based Predictive Model AIDPS for Prostate Cancer
Zhao Z, Yang Y, Sun Z, Fan L, Liu L |
Journal of Cellular and Molecular Medicine | 2025 |
|
TP53 Deficiency in the Natural History of Prostate Cancer
Ofner H, Kramer G, Shariat SF, Hassler MR |
Cancers | 2025 |
|
Distinct outcomes from targeted perturbations of the multi-subunit SCFSkp2 E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis
Xue Y, Zhu L, Karan S, Locker JD, Branch C, Zhang J, Hoang B, Maianti JP, Zhao H, Schwartz EL |
Communications Biology | 2025 |
|
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence
Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J |
Cell Reports Medicine | 2025 |
|
Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications
Vis DJ, Palit SA, Corradi M, Cuppen E, Mehra N, Lolkema MP, Wessels LF, van der Heijden MS, Zwart W, Bergman AM |
Genome Medicine | 2025 |
|
In Silico Design of Quantitative Polymerase Chain Reaction (qPCR) Assay Probes for Prostate Cancer Diagnosis, Prognosis, and Personalised Treatment
Wilson TK, Zishiri OT |
Current Issues in Molecular Biology | 2025 |
|
The role of recurrent somatic mutations that alter conserved m6A motifs in human cancer
Artz O, White JR, Rousseau B, Argiles G, Foote MB, Johannet P, Patel M, Abdelfattah S, Patel S, Wilde C, Mieles D, Diaz LA Jr |
NAR Cancer | 2025 |
|
Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer Therapy.
Alrouji M, Alshammari MS, Anwar S, Venkatesan K, Shamsi A |
Cancers | 2025 |
|
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers
Kwon WA, Joung JY |
Biomolecules | 2025 |
|
Development of PARP inhibitors in advanced prostate cancer
Bourlon MT, Valdez P, Castro E |
Therapeutic advances in medical oncology | 2024 |
|
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.
Warner EW, Van der Eecken K, Murtha AJ, Kwan EM, Herberts C, Sipola J, Ng SWS, Chen XE, Fonseca NM, Ritch E, Schönlau E, Bernales CQ, Donnellan G, Munzur AD, Parekh K, Beja K, Wong A, Verbeke S, Lumen N, Van Dorpe J, De Laere B, Annala M, Vandekerkhove G, Ost P, Wyatt AW |
Nature cancer | 2024 |
|
Towards accurate genomics for newly diagnosed metastatic prostate cancer.
|
Nature cancer | 2024 |
|
How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update
Baston C, Preda A, Iordache A, Olaru V, Surcel C, Sinescu I, Gingu C |
Cancers | 2024 |
|
Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review
Maekawa S, Takata R, Obara W |
Cancers | 2024 |
|
Identification of a basement membrane gene signature for predicting prognosis and estimating the tumor immune microenvironment in prostate cancer
Xie T, Fu DJ, Li KJ, Guo JD, Xiao ZM, Li Z, Zhao SC |
Aging | 2024 |
|
Molecular complexity of intraductal carcinoma of the prostate
Zhu S, Xu N, Zeng H |
Cancer Medicine | 2024 |
|
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A |
Cancer metastasis reviews | 2024 |
|
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
Ma J, Li L, Ma B, Liu T, Wang Z, Ye Q, Peng Y, Wang B, Chen Y, Xu S, Wang K, Dang F, Wang X, Zeng Z, Jian Y, Ren Z, Fan Y, Li X, Liu J, Gao Y, Wei W, Li L |
Nature Communications | 2024 |
|
Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer
Vandekerkhove G, Giri VN, Halabi S, McNair C, Hamade K, Bitting RL, Wyatt AW |
JCO Precision Oncology | 2024 |
|
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients
De Lazzari G, Opattova A, Arena S |
Journal of experimental & clinical cancer research : CR | 2024 |
|
Applications of Urinary Extracellular Vesicles in the Diagnosis and Active Surveillance of Prostate Cancer
Smith SF, Brewer DS, Hurst R, Cooper CS |
Cancers | 2024 |
|
Androgen receptor and estrogen receptor variants in prostate and breast cancers.
Valentín López JC, Lange CA, Dehm SM |
The Journal of Steroid Biochemistry and Molecular Biology | 2024 |
|
RARPKB: a knowledge-guide decision support platform for personalized robot-assisted surgery in prostate cancer
Li J, Tang T, Wu E, Zhao J, Zong H, Wu R, Feng W, Zhang K, Wang D, Qin Y, Shen Z, Qin Y, Ren S, Zhan C, Yang L, Wei Q, Shen B |
International journal of surgery (London, England) | 2024 |
|
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis
Yin J, Daryanani A, Lu F, Ku AT, Bright JR, Alilin AN, Bowman J, Lake R, Li C, Truong TM, Twohig JD, Mostaghel EA, Ishikawa M, Simpson M, Trostel SY, Corey E, Sowalsky AG, Kelly K |
The Prostate | 2024 |
|
PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer
Cunningham ML, Schiewer MJ |
Cancer research | 2024 |
|
Mechanism of baicalein in treatment of castration-resistant prostate cancer based on network pharmacology and cell experiments
Dou B, Cui Y, Zhou Q, Fu J, Zhou Y, Zhang X, Zhang Q, Zhang J |
Frontiers in pharmacology | 2024 |
|
Risk of Cancer-related Death for Men with Biopsy Grade Group 1 Prostate Cancer and High-risk Features: A European Multi-institutional Study
Milonas D, Giesen A, Muilwijk T, Soenens C, Devos G, Venclovas Z, Briganti A, Gontero P, Karnes RJ, Chlosta P, Claessens F, De Meerleer G, Everaerts W, Graefen M, Marchioro G, Sanchez-Salas R, Tombal B, Van Der Poel H, Van Poppel H, Spahn M, Joniau S |
2024 | |
|
PARP inhibitors alone or in combination for prostate cancer
Fenor de la Maza MD, Pérez Gracia JL, Miñana B, Castro E |
Therapeutic Advances in Urology | 2024 |
|
Metastatic hormone-naïve prostate cancer: a distinct biological entity
Corres-Mendizabal J, Zacchi F, Martín-Martín N, Mateo J, Carracedo A |
Trends in Cancer | 2024 |
|
Asparagine Dependency is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer
Yoo YA, Quan S, Yang W, Guo Q, Rodríguez Y, Chalmers ZR, Dufficy MF, Lackie B, Sagar V, Unno K, Truica MI, Chandel NS, Abdulkadir SA |
Cancer research | 2024 |
|
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).
Armstrong AJ, Taylor A, Haffner MC, Abida W, Bryce AH, Karsh LI, Tagawa ST, Twardowski P, Serritella AV, Lang JM |
Prostate cancer and prostatic diseases | 2024 |
|
Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments.
Wilson TK, Zishiri OT |
Cancer reports (Hoboken, N.J.) | 2024 |
|
Repeat Next Generation Sequencing (NGS) testing upon progression in men with metastatic prostate cancer can identify new actionable alterations
Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ |
JCO precision oncology | 2024 |
|
Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview.
Borges Dos Reis R, Aguilar-Ponce JL, Cayol F, Jansen AM, K RM, Merino TR, Sanku G, Vaca LB, Isaacsson Velho P, Korbenfeld EP |
Cancer control : journal of the Moffitt Cancer Center | 2024 |
|
Androgen-targeted hsa_circ_0085121 encodes a novel protein and improves the development of prostate cancer through facilitating the activity of PI3K/Akt/mTOR pathway and enhancing AR-V7 alternative splicing.
Li J, Qiu H, Dong Q, Yu H, Piao C, Li Z, Sun Y, Cui X |
Cell death & disease | 2024 |
|
Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer
Fanelli GN, Nuzzo PV, Pederzoli F, Loda M |
Surgical pathology clinics | 2024 |
|
Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer
Cordova RA, Sommers NR, Law AS, Klunk AJ, Brady KE, Goodrich DW, Anthony TG, Brault JJ, Pili R, Wek RC, Staschke KA |
Science signaling | 2024 |
|
Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence
Suzuki H, Akamatsu S, Shiota M, Kakiuchi H, Kimura T |
International Journal of Urology | 2024 |
|
Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma
Zhu S, Chen J, Zeng H |
Journal of Clinical Medicine | 2023 |
|
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting
Mehra N, Kloots I, Vlaming M, Aluwini S, Dewulf E, Oprea-Lager DE, van der Poel H, Stoevelaar H, Yakar D, Bangma CH, Bekers E, van den Bergh R, Bergman AM, van den Berkmortel F, Boudewijns S, Dinjens WN, Fütterer J, van der Hulle T, Jenster G, Kroeze LI, van Kruchten M, van Leenders G, van Leeuwen PJ, de Leng WW, van Moorselaar RJ, Noordzij W, Oldenburg RA, van Oort IM, Oving I, Schalken JA, Schoots IG, Schuuring E, Smeenk RJ, Vanneste BG, Vegt E, Vis AN, de Vries K, Willemse PP, Wondergem M, Ausems M |
2023 | |
|
Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis
Ashraf MU, Farwa U, Siddiqa M, Sarfraz A, Azeem N, Sarfraz Z |
2023 | |
|
Advances in PARP Inhibitors for Prostate Cancer
Tisseverasinghe S, Bahoric B, Anidjar M, Probst S, Niazi T |
Cancers | 2023 |
|
Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H |
Cancer Medicine | 2023 |
|
Management of Advanced Prostate Cancer in the Precision Oncology Era
Gillette CM, Yette GA, Cramer SD, Graham LS |
Cancers | 2023 |
|
Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
Valsecchi AA, Dionisio R, Panepinto O, Paparo J, Palicelli A, Vignani F, Di Maio M |
Cancers | 2023 |
|
Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer.
Du X, Fei X, Wang J, Dong Y, Fan L, Yang B, Chen W, Gong Y, Xia B, Zhu H, Wu F, Wang Y, Dong L, Zhu Y, Pan J, Yao X, Dong B |
Translational oncology | 2023 |
|
Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans
Valle LF, Nickols NG, Hausler R, Alba PR, Anglin-Foote T, Perez C, Yamoah K, Rose BS, Kelley MJ, DuVall SL, Garraway IP, Maxwell KN, Lynch JA |
The oncologist | 2023 |
|
Impact of DNA damage repair alterations on prostate cancer progression and metastasis.
Lukashchuk N, Barnicle A, Adelman CA, Armenia J, Kang J, Barrett JC, Harrington EA |
Frontiers in Oncology | 2023 |
|
Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated “Omics” Approaches to Explore Measurable Metrics
Logotheti S, Papadaki E, Zolota V, Logothetis C, Vrahatis AG, Soundararajan R, Tzelepi V |
Cancers | 2023 |
|
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
Wei Y, Zhang T, Wang B, Pan J, Jin S, Fang B, Gu W, Qin X, Dai B, Lin G, Gan H, Wu J, Ye D, Zhu Y |
Molecular Oncology | 2023 |
|
De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
Piombino C, Oltrecolli M, Tonni E, Pirola M, Matranga R, Baldessari C, Pipitone S, Dominici M, Sabbatini R, Vitale MG |
Cancers | 2023 |
|
Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.
Bruin MAC, Mohmaed Ali MI, van Nuland M, Jacobs BAW, Lucas L, Dezentje VO, de Feijter JM, Rosing H, Bergman AM, Beijnen JH, Huitema ADR |
Pharmaceutical Research | 2023 |
|
Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer
Wang R, Xu Q, Guo H, Yang G, Zhang J, Wang H, Xu T, Guo C, Yuan J, He Y, Zhang X, Fu H, Xu G, Zhao B, Xie J, Zhao T, Huang L, Zhang J, Peng B, Yao X, Yang B |
2023 | |
|
Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities
Yu EM, Hwang MW, Aragon-Ching JB |
Research and Reports in Urology | 2023 |
|
Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis
Moreno CS, Winham CL, Alemozaffar M, Klein ER, Lawal IO, Abiodun-Ojo OA, Patil D, Barwick BG, Huang Y, Schuster DM, Sanda MG, Osunkoya AO |
Cancers | 2023 |
|
Establishment and characterization of NCC-PMP2-C1: a novel patient-derived cell line of pseudomyxoma peritonei with signet ring cells.
Noguchi R, Yoshimatsu Y, Sin Y, Ono T, Tsuchiya R, Yoshida H, Kiyono T, Yonemura Y, Kondo T |
Human Cell | 2023 |
|
Establishment of novel ferroptosis-related prognostic subtypes correlating with immune dysfunction in prostate cancer patients
Feng D, Tuo Z, Wang J, Ye L, Li D, Wu R, Wei W, Yang Y, Zhang C |
Heliyon | 2023 |
|
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer
Calabrese M, Saporita I, Turco F, Gillessen S, Castro E, Vogl UM, Di Stefano RF, Carfì FM, Poletto S, Farinea G, Tucci M, Buttigliero C |
International journal of molecular sciences | 2023 |
|
Exploiting the DNA Damage Response for Prostate Cancer Therapy
Stracker TH, Osagie OI, Escorcia FE, Citrin DE |
Cancers | 2023 |
|
Valeur pronostique de la protéine p53 dans le cancer de la prostate
Ben Rejeb S, Kouki N, Elfekih S, Cherif I, Khouni H |
La Tunisie Médicale | 2023 |
|
Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis
W Zhang, T Wang, Y Wang, F Zhu, H Shi, J Zhang, Z Wang, M Qu, H Zhang, T Wang, Y Qian, J Yang, X Gao, J Li |
Translational oncology | 2022 |
|
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression
W Gesztes, C Schafer, D Young, J Fox, J Jiang, Y Chen, H Kuo, K Mwamukonda, A Dobi, A Burke, J Moul, D McLeod, I Rosner, G Petrovics, S Tan, J Cullen, S Srivastava, I Sesterhenn |
Scientific Reports | 2022 |
|
Alpha Satellite RNA Levels Are Upregulated in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer
S Ljubić, A Sermek, A Sečan, M Prpić, B Jakšić, J Murgić, A Fröbe, Đ Ugarković, I Feliciello |
Genes & development | 2022 |
|
RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition
W Han, M Liu, D Han, M Li, AA Toure, Z Wang, A Besschetnova, S Patalano, JA Macoska, S Gao, HH He, C Cai |
Oncogene | 2022 |
|
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
D Teyssonneau, A Thiery-Vuillemin, C Dariane, E Barret, J Beauval, L Brureau, G Créhange, G Fiard, G Fromont, M Gauthé, A Ruffion, R Renard-Penna, R Mathieu, P Sargos, M Rouprêt, G Ploussard, G Roubaud |
Journal of Clinical Medicine | 2022 |
|
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
T Powles, K Yuen, S Gillessen, E Kadel, D Rathkopf, N Matsubara, C Drake, K Fizazi, J Piulats, P Wysocki, G Buchschacher, B Alekseev, B Mellado, B Karaszewska, J Doss, G Rasuo, A Datye, S Mariathasan, P Williams, C Sweeney |
Nature Medicine | 2022 |
|
Effect of Clinical Parameters on Risk of Death from Cancer after Radical Prostatectomy in Men with Localized and Locally Advanced Prostate Cancer
D Milonas, T Ruzgas, Z Venclovas, D Jonusaite, A Matijosaitis, D Trumbeckas, E Varpiotas, S Auskalnis, D Skaudickas, R Mickevicius, K Vaiciunas, J Mickevicius, M Jievaltas |
Cancers | 2022 |
|
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer
Nevedomskaya E, Haendler B |
International journal of molecular sciences | 2022 |
|
Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience
Youssef AS, Abdel-Fattah MA, Lotfy MM, Nassar A, Abouelhoda M, Touny AO, Hassan ZK, Mohey Eldin M, Bahnassy AA, Khaled H, Zekri AR |
Current issues in molecular biology | 2022 |
|
Precision intervention for prostate cancer: re-evaluating who is at risk
Papachristodoulou A, Abate-Shen C |
Cancer Letters | 2022 |
|
A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies
Serelli-Lee V, Ito K, Koibuchi A, Tanigawa T, Ueno T, Matsushima N, Imai Y |
Journal of Personalized Medicine | 2022 |
|
Genomic Biomarkers to Guide Precision Radiotherapy in Prostate Cancer
Sutera P, Deek MP, Van der Eecken K, Wyatt AW, Kishan AU, Molitoris JK, Ferris MJ, Minhaj Siddiqui M, Rana Z, Mishra MV, Kwok Y, Davicioni E, Spratt DE, Ost P, Feng FY, Tran PT |
The Prostate | 2022 |
|
Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
Mirzaei S, Paskeh MD, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y |
Journal of experimental & clinical cancer research : CR | 2022 |
|
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
van Wilpe S, Simnica D, Slootbeek P, van Ee T, Pamidimarri Naga S, Gorris MA, van der Woude LL, Sultan S, Koornstra RH, van Oort IM, Gerritsen WR, Kroeze LI, Simons M, van Leenders GJ, Binder M, de Vries IJ, Mehra N |
OncoImmunology | 2022 |
|
N-glycosylation of GDF15 abolishes its inhibitory effect on EGFR in AR inhibitor-resistant prostate cancer cells
Wang R, Wen P, Yang G, Feng Y, Mi Y, Wang X, Zhu S, Chen YQ |
Cell Death and Disease | 2022 |
|
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RS, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J |
JCO Precision Oncology | 2022 |
|
Detection of disease‐causing mutations in prostate cancer by NGS sequencing
Mangolini A, Rocca C, Bassi C, Ippolito C, Negrini M, Dell'Atti L, Lanza G, Gafà R, Bianchi N, Pinton P, Aguiari G |
Cell biology international | 2022 |
|
Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer
Mao Y, Yang G, Li Y, Liang G, Xu W, Hu M |
Cancers | 2022 |
|
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Boussios S, Rassy E, Moschetta M, Ghose A, Adeleke S, Sanchez E, Sheriff M, Chargari C, Pavlidis N |
Cancers | 2022 |
|
Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
Zhou J, Lai Y, Peng S, Tang C, Chen Y, Li L, Huang H, Guo Z |
Frontiers in Oncology | 2022 |
|
Cathepsin K regulates the tumor growth and metastasis by IL-17/CTSK/EMT axis and mediates M2 macrophage polarization in castration-resistant prostate cancer
Wu N, Wang Y, Wang K, Zhong B, Liao Y, Liang J, Jiang N |
Cell Death and Disease | 2022 |
|
MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development
Li W(, Liu X, Dougherty EM, Tang DG |
Cancers | 2022 |
|
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N |
Frontiers in Oncology | 2022 |
|
Ubiquitin-related lncRNAs: The new tool for prognosis prediction in prostate cancer
Liu X, Mei W, Jin L, Sun X, Zhou Z, Xin S, Huang L, Yang G, Wang J, Ye L |
Frontiers in Oncology | 2022 |
|
PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
McNevin CS, Cadoo K, Baird AM, Finn SP, McDermott R |
Cancers | 2022 |
|
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
Jiménez N, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domenech M, Figols M, González-Billalabeitia E, Jiménez Peralta D, Rodríguez-Carunchio L, García-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B |
Cancers | 2022 |
|
Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.
Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z, Zhang X, Ren X, Wang S, Qin C |
Cancer control : journal of the Moffitt Cancer Center | 2022 |
|
Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.
Pallasaho S, Gondane A, Kuivalainen A, Girmay S, Moestue S, Loda M, Itkonen HM |
Journal of Cancer Research and Clinical Oncology | 2022 |
|
Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
Wang Z, Yan X, Tang P, Tang T, Wang Y, Peng S, Wang S, Lan W, Wang L, Zhang Y, Zhang J, Li K, Shu Z, Xu J, Qin J, Zhang D, Jiang J, Liu Q |
Prostate Cancer and Prostatic Diseases | 2022 |
|
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
Inderjeeth AJ, Topp M, Sanij E, Castro E, Sandhu S |
Cancers | 2022 |
|
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M |
Clinical cancer research | 2022 |
|
Future directions for precision oncology in prostate cancer
Mizuno K, Beltran H |
The Prostate | 2022 |
|
GENOMICS OF PROSTATE CANCER: CLINICAL UTILITY AND CHALLENGES
Šamija I, Fröbe A |
Acta clinica Croatica | 2022 |
|
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, Koto R, Takahashi M, Nii M, Shin E, Nonomura N |
Cancer Medicine | 2022 |
|
Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis.
Shree B, Das K, Sharma V |
2022 | |
|
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
V Conteduca, A Mosca, N Brighi, U de Giorgi, P Rescigno |
Cells | 2021 |
|
Molecular Characterization of Prostate Cancers in the Precision Medicine Era
EF Giunta, L Annaratone, E Bollito, F Porpiglia, M Cereda, GL Banna, A Mosca, C Marchiò, P Rescigno |
Cancers | 2021 |
|
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer
PL Palmbos, S Daignault-Newton, SA Tomlins, N Agarwal, P Twardowski, AK Morgans, WK Kelly, VK Arora, ES Antonarakis, J Siddiqui, JA Jacobson, MS Davenport, DR Robinson, AM Chinnaiyan, KE Knudsen, M Hussain |
Clinical cancer research | 2021 |
|
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA
MT Schweizer, S Sivakumar, H Tukachinsky, I Coleman, ND Sarkar, EY Yu, EQ Konnick, PS Nelson, CC Pritchard, B Montgomery |
JAMA Oncology | 2021 |
|
Identification of a Costimulatory Molecule-Related Signature for Predicting Prognostic Risk in Prostate Cancer
S Ge, X Hua, J Chen, H Xiao, L Zhang, J Zhou, C Liang, S Tai |
Frontiers in Genetics | 2021 |
|
Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation
JM Pardo-Sánchez, N Mancheño, J Cerón, C Jordá, E Ansotegui, Ó Juan, S Palanca, A Cremades, C Gandía, R Farràs |
Cancers | 2021 |
|
Resistance to second-generation androgen receptor antagonists in prostate cancer
KT Schmidt, AD Huitema, CH Chau, WD Figg |
Nature Reviews Urology | 2021 |
|
Clinical implications of genomic alterations in metastatic prostate cancer
T Sumiyoshi, KN Chi, AW Wyatt |
Prostate Cancer and Prostatic Diseases | 2021 |
|
Prostate cancer and PARP inhibitors: progress and challenges
D Teyssonneau, H Margot, M Cabart, M Anonnay, P Sargos, NS Vuong, I Soubeyran, N Sevenet, G Roubaud |
Journal of Hematology & Oncology | 2021 |
|
MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1
LK Jillson, LC Rider, LU Rodrigues, L Romero, A Karimpour-Fard, C Nieto, C Gillette, K Torkko, E Danis, EE Smith, R Nolley, DM Peehl, MS Lucia, JC Costello, SD Cramer |
Molecular cancer research : MCR | 2021 |
|
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
C Cattrini, R España, A Mennitto, M Bersanelli, E Castro, D Olmos, D Lorente, A Gennari |
Cancers | 2021 |
|
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
TH Carr, C Adelman, A Barnicle, I Kozarewa, S Luke, Z Lai, S Hollis, B Dougherty, EA Harrington, J Kang, F Saad, N Sala, A Thiery-Vuillemin, NW Clarke, D Hodgson, JC Barrett |
Cancers | 2021 |
|
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
S Sumanasuriya, G Seed, H Parr, R Christova, L Pope, C Bertan, D Bianchini, P Rescigno, I Figueiredo, J Goodall, G Fowler, P Flohr, N Mehra, A Neeb, J Rekowski, M Eisenberger, O Sartor, S Oudard, C Geffriaud-Ricouard, A Ozatilgan, M Chadjaa, S Macé, Chris, J Baxter, S Pettitt, M Lambros, A Sharp, J Mateo, S Carreira, W Yuan, J de Bono |
European Urology | 2021 |
|
Differential Activity of PARP Inhibitors in BRCA1 - Versus BRCA2 -Altered Metastatic Castration-Resistant Prostate Cancer
F Taza, A Holler, W Fu, H Wang, N Adra, C Albany, R Ashkar, H Cheng, A Sokolova, N Agarwal, A Kessel, A Bryce, N Nafissi, P Barata, A Sartor, D Bastos, O Smaletz, J Berchuck, M Taplin, R Aggarwal, C Sternberg, P Vlachostergios, A Alva, C Su, C Marshall, E Antonarakis |
JCO Precision Oncology | 2021 |
|
Synthetic Retinoids as Potential Therapeutics in Prostate Cancer—An Update of the Last Decade of Research: A Review
P Hałubiec, A Łazarczyk, O Szafrański, T Bohn, J Dulińska-Litewka |
International journal of molecular sciences | 2021 |
|
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
A Loehr, A Patnaik, D Campbell, J Shapiro, A Bryce, R McDermott, B Sautois, N Vogelzang, R Bambury, E Voog, J Zhang, J Piulats, A Hussain, C Ryan, A Merseburger, G Daugaard, A Heidenreich, K Fizazi, C Higano, L Krieger, C Sternberg, S Watkins, D Despain, A Simmons, M Dowson, T Golsorkhi, S Chowdhury, W Abida |
Clinical cancer research | 2021 |
|
Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
K van der Zande, W Oyen, W Zwart, A Bergman |
Cancers | 2021 |
|
Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence
N Giraud, X Buy, N Vuong, R Gaston, A Cazeau, V Catena, J Palussiere, G Roubaud, P Sargos |
Frontiers in Oncology | 2021 |
|
Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease
S Walker, R Abdelsalam, S Ghosh, J Livingstone, N Palanisamy, P Boutros, S Yip, S Lees-Miller, T Bismar |
2021 | |
|
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
U Giorgi, M Sansovini, S Severi, S Nicolini, M Monti, G Gurioli, F Foca, C Casadei, V Conteduca, M Celli, V Iorio, D Calistri, F Matteucci, F von Eyben, G Attard, G Paganelli |
British Journal of Cancer | 2021 |
|
Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine
S Kamran, J Efstathiou |
Frontiers in Oncology | 2021 |
|
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment
E Boerrigter, G Benoist, I Oort, G Verhaegh, O Hooij, L Groen, F Smit, I Oving, P Mol, T Smilde, D Somford, N Mehra, J Schalken, N Erp |
Molecular Oncology | 2021 |
|
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
D Gonzalez, J Mateo, A Stenzinger, F Rojo, M Shiller, A Wyatt, F PenaultLlorca, L Gomella, R Eeles, A Bjartell |
The Journal of Pathology: Clinical Research | 2021 |
|
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration
B Yang, J Chen, Y Teng, Y Yu |
Journal of Immunology Research | 2021 |
|
Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C
E Thysell, L Köhn, J Semenas, H Järemo, E Freyhult, M Lundholm, C Karlsson, J Damber, A Widmark, S Crnalic, A Josefsson, K Welén, R Nilsson, A Bergh, P Wikström |
Molecular Oncology | 2021 |
|
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
P Slootbeek, I Kloots, M Smits, I van Oort, W Gerritsen, J Schalken, M Ligtenberg, K Grünberg, L Kroeze, H Bloemendal, N Mehra |
British Journal of Cancer | 2021 |
|
Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context
M Kolinsky, K Niederhoffer, E Kwan, S Hotte, Z Hamilou, S Yip, K Chi, A Wyatt, F Saad |
Canadian Urological Association Journal | 2021 |
|
Genomic Profiling of Prostate Cancer: An Updated Review
Hatano K, Nonomura N |
The World Journal of Men's Health | 2021 |
|
The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
Boerrigter E, Benoist GE, Overbeek JK, Donders R, Mehra N, van Oort IM, ter Heine R, van Erp NP |
British Journal of Clinical Pharmacology | 2021 |
|
Genomic analysis of circulating tumor DNA in patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms
Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR |
Clinical cancer research | 2021 |
|
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS |
Cancer Discovery | 2021 |
|
Prostate cancer.
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG |
Nature Reviews Disease Primers | 2021 |
|
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
Deek MP, Van der Eecken K, Phillips R, Parikh NR, Velho PI, Lotan TL, Kishan AU, Maurer T, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P, Tran PT |
European Urology | 2021 |
|
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA
EN Risdon, CH Chau, DK Price, O Sartor, WD Figg |
The oncologist | 2020 |
|
CDK12: A Potent Target and Biomarker for Human Cancer Therapy
S Liang, L Hu, Z Wu, Z Chen, S Liu, X Xu, A Qian |
Cells | 2020 |
|
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
TA Yap, DS Tan, A Terbuch, R Caldwell, C Guo, BC Goh, V Heong, N R.Haris, S Bashir, Y Drew, DS Hong, F Meric-Bernstam, G Wilkinson, J Hreiki, AM Wengner, F Bladt, A Schlicker, M Ludwig, Y Zhou, L Liu, S Bordia, R Plummer, E Lagkadinou, JS de Bono |
Cancer Discovery | 2020 |
|
Accelerating precision medicine in metastatic prostate cancer
J Mateo, R McKay, W Abida, R Aggarwal, J Alumkal, A Alva, F Feng, X Gao, J Graff, M Hussain, F Karzai, B Montgomery, W Oh, V Patel, D Rathkopf, M Rettig, N Schultz, M Smith, D Solit, C Sternberg, EV Allen, D VanderWeele, J Vinson, HR Soule, A Chinnaiyan, E Small, JW Simons, W Dahut, AK Miyahira, H Beltran |
2020 | |
|
Genomic and phenotypic heterogeneity in prostate cancer
MC Haffner, W Zwart, MP Roudier, LD True, WG Nelson, JI Epstein, AM Marzo, PS Nelson, S Yegnasubramanian |
Nature Reviews Urology | 2020 |
|
Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers
MA Rubin, RG Bristow, PD Thienger, C Dive, M Imielinski |
Molecular Cell | 2020 |
|
Genomic and Clinicopathologic Characterization of ATM -deficient Prostate Cancer
H Kaur, DC Salles, S Murali, JL Hicks, M Nguyen, CC Pritchard, AM Marzo, JS Lanchbury, BJ Trock, WB Isaacs, KM Timms, ES Antonarakis, TL Lotan |
Clinical cancer research | 2020 |
|
CDK12: cellular functions and therapeutic potential of versatile player in cancer
K Pilarova, J Herudek, D Blazek |
2020 | |
|
TP53 alterations of hormone-naïve prostate cancer in the Chinese population
Z Liu, H Guo, Y Zhu, Y Xia, J Cui, K Shi, Y Fan, B Shi, S Chen |
Prostate Cancer and Prostatic Diseases | 2020 |
|
Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration‐Sensitive Prostate Cancer
Y Wei, J Wu, W Gu, J Wang, G Lin, X Qin, B Dai, H Gan, D Ye, Y Zhu |
The oncologist | 2020 |
|
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer
A Carlson, R Acevedo, D Lim, R Gulati, A Gawne, A Sokolova, H Cheng, P Nelson, R Montgomery, E Yu, M Schweizer, A Galli |
PloS one | 2020 |
|
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
C Messina, C Cattrini, D Soldato, G Vallome, O Caffo, E Castro, D Olmos, F Boccardo, E Zanardi |
Journal of Oncology | 2020 |
|
Clinical Applications of Molecular Biomarkers in Prostate Cancer
F Couñago, F López-Campos, A Díaz-Gavela, E Almagro, E Fenández-Pascual, I Henríquez, R Lozano, E Espinós, A Gómez-Iturriaga, G de Velasco, L Franco, I Rodríguez-Melcón, J López-Torrecilla, D Spratt, L Guerrero, J Martínez-Salamanca, E del Cerro |
Cancers | 2020 |
|
Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer
C Cattrini, P Barboro, A Rubagotti, L Zinoli, E Zanardi, M Capaia, F Boccardo |
Translational oncology | 2020 |
|
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
K Stopsack, S Nandakumar, A Wibmer, S Haywood, E Weg, E Barnett, C Kim, E Carbone, S Vasselman, B Nguyen, M Hullings, H Scher, M Morris, D Solit, N Schultz, P Kantoff, W Abida |
Clinical cancer research | 2020 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)